Skip to main content
Portfolio
TrendingElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentionsFinance

Tech & Science

PredictLive133AccountSocial
MARKETSINVESTLIVE133

Medicine

Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
All markets
AI
Big Tech & Business
Education
Energy
Market Share
Medicine
Physics & Math
Public Health
Space
Tokens

Tech and science odds and guides

Best AI model oddsRelease dates for AI models and gadgets

When will the FDA approve Compass Pathways’ COMP360 Psilocybin?

Before Mar 1, 2027
1.34x
Before Jan 1, 2027
4.31x
$27,636 vol

Will the FDA approve retatrutide?

Before Jan 1, 2028
1.38x
Before Jan 1, 2029
1.10x
$119,178 vol

Will the FDA approve CagriSema?

Before Jul 1, 2027
1.08x
Before Jan 1, 2028
1.05x
$11,514 vol

When will Beam Therapeutics submit a BLA for Risto-cel?

before 2027
1.93x
before April 2027
1.13x
$30,810 vol

When will Compass Pathways submit a NDA for COMP360 psilocybin?

before December
1.02x
before April 2027
--
$41,667 vol

Will the FDA approve a cure for Type 1 diabetes before 2033?

Yes
2.29x
No
1.55x
$10,927 vol

When will the FDA approve Intellia Therapeutics’ lonvo-z?

Before July 2027
1.10x
Before October 2027
1.07x
$6,564 vol

Will the FDA approve VERVE-102?

Before 2030
1.73x
Before 2031
1.42x
$1,819 vol

When will the FDA reclassify BPC-157 to Category 1?

Yes
15.6x
No
1.03x
$147,976 vol